Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI aims to revolutionize cancer trial enrollment for 50,000 patients

NCT ID NCT03452774

Knowledge-focused Sponsor: Massive Bio, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make it easier for patients to find and join studies that might benefit them.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2018

Expected to finish

Jun 2040

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Observational cohort study of eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider clinical trial enrollment (CTE) has already been made by their primary providers (PP).

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2/Neu, Tumor mutational burden/load (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A/B, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1/2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA/B/C, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others. These biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform * Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and/or patient Exclusion Criteria: * ECOG PS \> 2; * Abnormal organ function; * Hospice enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm cancer carcinoma carcinoma of liver and intrahepatic biliary tract central nervous system cancer cervical carcinoma cholangiocarcinoma colonic neoplasm COVID-19 endometrial cancer endometrium neoplasm esophageal cancer Esophageal Neoplasms follicular lymphoma gastric cancer gastric neoplasm glioblastoma Head and Neck Neoplasms hematopoietic and lymphoid cell neoplasm hepatocellular carcinoma kidney cancer laryngeal carcinoma laryngeal neoplasm leukemia liver cancer Liver Neoplasms lung cancer lung carcinoma lung neoplasm Lymphoma, B-Cell, Marginal Zone malignant colon neoplasm malignant pancreatic neoplasm malignant tumor of neck mantle cell lymphoma marginal zone lymphoma melanoma metastatic malignant neoplasm mismatch repair cancer syndrome 1 myelodysplastic syndrome Myelodysplastic Syndromes myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm neoplasm Neoplasm Metastasis neuroendocrine neoplasm non-Hodgkin lymphoma non-small cell lung carcinoma ovarian cancer pancreatic neoplasm primary myelofibrosis prostate cancer rectal cancer rectal neoplasm skin cancer skin neoplasm testicular cancer transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer BRCA gene rearrangement Breast cancer Cancer Cancer liver Cancer metastatic Cancer of cervix Cancer of colon Cancer of esophagus Cancer of kidney Cancer of larynx Cancer of liver Cancer of neck Cancer of pancreas Cancer of rectum Cancer of skin Cancer of stomach Cancer prostate Cancer, advanced Cancer, breast Cancer, lung Carcinoma Central nervous system tumor Cholangiocarcinoma COVID Endometrial cancer Follicular lymphoma Glioblastoma Leukemia Mantle cell lymphoma Marginal zone lymphoma Melanoma Mismatch repair deficiency Myelodysplastic syndromes Myelofibrosis Myeloproliferative disorders Myeloproliferative neoplasm Neuroendocrine tumors Non-Hodgkin lymphoma Non-small cell lung cancer Ovarian cancer Testicular cancer Urothelial carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    68 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Birmingham, Alabama, 35294, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Mobile, Alabama, 36604, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Scottsdale, Arizona, 85260, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Little Rock, Arkansas, 72205, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Duarte, California, 91010, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Irvine, California, 92618, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    La Jolla, California, 92093, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Orange, California, 92868, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    San Francisco, California, 94143, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Stanford, California, 94305, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Aurora, Colorado, 80045, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Denver, Colorado, 80218, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Littleton, Colorado, 80129, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Hartford, Connecticut, 06102, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Norwalk, Connecticut, 06856, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Newark, Delaware, 19713, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Miami, Florida, 33136, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Tampa, Florida, 33612, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Savannah, Georgia, 31405, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Boise, Idaho, 83706, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    New Orleans, Louisiana, 70112, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Scarborough, Maine, 04074, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Baltimore, Maryland, 21218, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Bethesda, Maryland, 20892, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Silver Spring, Maryland, 20904, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Towson, Maryland, 21204, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Worcester, Massachusetts, 01655, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Lansing, Michigan, 48912, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Duluth, Minnesota, 55805, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Hattiesburg, Mississippi, 39401, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Kansas City, Missouri, 64111, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    St Louis, Missouri, 63110, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Billings, Montana, 59102, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Omaha, Nebraska, 68124, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Albuquerque, New Mexico, 87131, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Buffalo, New York, 14263, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Hempstead, New York, 11042, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Manhasset, New York, 11030, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    New York, New York, 10006, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Staten Island, New York, 10314, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Winston-Salem, North Carolina, 27157, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Fargo, North Dakota, 58102, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Cincinnati, Ohio, 45219, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Mayfield Heights, Ohio, 44124, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Tulsa, Oklahoma, 74146, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Portland, Oregon, 97239, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Philadelphia, Pennsylvania, 19044, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Providence, Rhode Island, 02903, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Greenville, South Carolina, 29605, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Memphis, Tennessee, 38105, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Dallas, Texas, 75246, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Houston, Texas, 77030, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Temple, Texas, 76508, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Charlottesville, Virginia, 22908, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Seattle, Washington, 98109, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Morgantown, West Virginia, 26506, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Massive Bio SYNERGY-AI site

    RECRUITING

    San Juan, 00917, Puerto Rico

More trials for these conditions

Other studies related to the condition(s) this trial covers.